Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study

被引:12
作者
Lin, Dan-Yu [1 ,4 ]
Xu, Yangjianchen [1 ]
Gu, Yu [1 ]
Zeng, Donglin [1 ]
Wheeler, Bradford [2 ]
Young, Hayley [2 ]
Moore, Zack [2 ]
Sunny, Shadia K. [3 ]
机构
[1] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA
[2] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA
[3] Ctr Dis Control & Prevent Fdn, North Carolina Dept Hlth & Human Serv, Raleigh, NC USA
[4] Univ N Carolina, Dept Biostat, Gillings Sch Publ Hlth, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
REGRESSION;
D O I
10.1016/S1473-3099(23)00272-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Data on the protection conferred by COVID-19 vaccination and previous SARS-CoV-2 infection against omicron (B.1.1.529) infection in young children are scarce. We aimed to estimate the time-varying effects of primary and booster COVID-19 vaccination and previous SARS-CoV-2 infection on subsequent omicron infection and severe illness (hospital admission or death) in children younger than 12 years of age.Methods In this observational cohort study, we obtained individual-level records on vaccination with the BNT162b2 and mRNA-1273 vaccines and clinical outcomes from the North Carolina COVID-19 Surveillance System and the COVID-19 Vaccine Management System for 1 368 721 North Carolina residents aged 11 years or younger from Oct 29, 2021 (Oct 29, 2021 for children aged 5-11 years and June 17, 2022 for children aged 0-4 years), to Jan 6, 2023. We used Cox regression to estimate the time-varying effects of primary and booster vaccination and previous infection on the risks of omicron infection, hospital admission, and death.Findings For children 5-11 years of age, the effectiveness of primary vaccination against infection, compared with being unvaccinated, was 59 center dot 9% (95% CI 58 center dot 5-61 center dot 2) at 1 month, 33 center dot 7% (32 center dot 6-34 center dot 8) at 4 months, and 14 center dot 9% (95% CI 12 center dot 3-17 center dot 5) at 10 months after the first dose. Compared with primary vaccination only, the effectiveness of a monovalent booster dose after 1 month was 24 center dot 4% (14 center dot 4-33 center dot 2) and that of a bivalent booster dose was 76 center dot 7% (45 center dot 7-90 center dot 0). The effectiveness of omicron infection against reinfection was 79 center dot 9% (78 center dot 8-80 center dot 9) after 3 months and 53 center dot 9% (52 center dot 3-55 center dot 5) after 6 months. For children 0-4 years of age, the effectiveness of primary vaccination against infection, compared with being unvaccinated, was 63 center dot 8% (57 center dot 0-69 center dot 5) at 2 months and 58 center dot 1% (48 center dot 3-66 center dot 1) at months after the first dose, and the effectiveness of omicron infection against reinfection was 77 center dot 3% (75 center dot 9-78 center dot 6) after 3 months and 64 center dot 7% (63 center dot 3-66 center dot 1) after 6 months. For both age groups, vaccination and previous infection had better effectiveness against severe illness as measured by hospital admission or death as a composite endpoint than against infection. Interpretation The BNT162b2 and mRNA-1273 vaccines were effective against omicron infection and severe outcomes in children younger than 12 years, although the effectiveness decreased over time. Bivalent boosters were more effective than monovalent boosters. Immunity acquired via omicron infection was high and waned gradually over time. These findings can be used to develop effective prevention strategies against COVID-19 in children younger than 12 years.Copyright (c) 2023 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1257 / 1265
页数:9
相关论文
共 30 条
  • [1] Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
    Abu-Raddad, L. J.
    Chemaitelly, H.
    Ayoub, H. H.
    AlMukdad, S.
    Yassine, H. M.
    Al-Khatib, H. A.
    Smatti, M. K.
    Tang, P.
    Hasan, M. R.
    Coyle, P.
    Al-Kanaani, Z.
    Al-Kuwari, E.
    Jeremijenko, A.
    Kaleeckal, A. H.
    Latif, A. N.
    Shaik, R. M.
    Abdul-Rahim, H. F.
    Nasrallah, G. K.
    Al-Kuwari, M. G.
    Butt, A. A.
    Al-Romaihi, H. E.
    Al-Thani, M. H.
    Al-Khal, A.
    Bertollini, R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (19) : 1804 - 1816
  • [2] Who wants his dose?
    不详
    [J]. EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2023, (193): : 239 - 240
  • [3] Altarawneh HN, 2022, NEW ENGL J MED, DOI 10.1056/NEJMc2209306
  • [4] Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
    Altarawneh, Heba N.
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Smatti, Maria K.
    Coyle, Peter
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01) : 21 - 34
  • [5] Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study
    Amir, Ofra
    Goldberg, Yair
    Mandel, Micha
    Bar-On, Yinon M.
    Bodenheimer, Omri
    Freedman, Laurence
    Ash, Nachman
    Alroy-Preis, Sharon
    Huppert, Amit
    Milo, Ron
    [J]. LANCET INFECTIOUS DISEASES, 2023, 23 (01) : 67 - 73
  • [6] Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
    Anderson, E. J.
    Creech, C. B.
    Berthaud, V
    Piramzadian, A.
    Johnson, K. A.
    Zervos, M.
    Garner, F.
    Griffin, C.
    Palanpurwala, K.
    Turner, M.
    Gerber, J.
    Bennett, R. L.
    Ali, K.
    Ampajwala, M.
    Berman, G.
    Nayak, J.
    Chronis, C.
    Rizzardi, B.
    Muller, W. J.
    Smith, C. A.
    Fuchs, G.
    Hsia, D.
    Tomassini, J. E.
    DeLucia, D.
    Reuter, C.
    Kuter, B.
    Zhao, X.
    Deng, W.
    Zhou, H.
    Schrempp, D. Ramirez
    Hautzinger, K.
    Girard, B.
    Slobod, K.
    McPhee, R.
    Pajon, R.
    Aunins, A.
    Das, R.
    Miller, J. M.
    Ghamloush, S. Schnyder
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18) : 1673 - 1687
  • [7] Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
  • [8] Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
    Bar-On, Yinon M.
    Goldberg, Yair
    Mandel, Micha
    Bodenheimer, Omri
    Amir, Ofra
    Freedman, Laurence
    Alroy-Preis, Sharon
    Ash, Nachman
    Huppert, Amit
    Milo, Ron
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18) : 1712 - 1720
  • [9] Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies
    Buonsenso, Danilo
    Cusenza, Francesca
    Passadore, Lucrezia
    Bonanno, Francesca
    De Guido, Claudia
    Esposito, Susanna
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [10] Covid-19 Vaccine Protection among Children and Adolescents in Qatar
    Chemaitelly, Hiam
    AlMukdad, Sawsan
    Ayoub, Houssein H.
    Altarawneh, Heba N.
    Coyle, Peter
    Tang, Patrick
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Smatti, Maria K.
    Hasan, Mohammad R.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Al-Romaihi, Hamad E.
    Butt, Adeel A.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (20) : 1865 - 1876